Foundation Medicine-B executives Yang Jianxin and senior executives increased their holdings of 2.42 million shares.

Basestone Pharmaceuticals-B announced that the company's CEO, Chief Scientific Officer, and Executive Director Yang Jianxin, along with other directors and senior management, have collectively purchased 2.42 million shares in the public market in June 2026, with Dr. Yang purchasing 1.2375 million shares. Since assuming the position of CEO in August 2022, Dr. Yang has accumulated a total of 13.7145 million shares through purchases in the public market. Following the increase in shares, as of the date of this announcement, Dr. Yang holds a total of approximately 5.26% of the company's issued share capital.